ClinicaliQ Trial Snapshot
- A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa — Active Not Recruiting • Phase III • NCT06840392.
- Remibrutinib reduces symptoms of severe hidradenitis suppurativa better than placebo, with acceptable safety in adults and teenagers.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS). Conditions: Hidradenitis Suppurativa Interventions: Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2 Lead Sponsor: Novartis Pharmaceuticals Planned Enrollment: 565 participants